LEGN Stock On Track For Worst Day Ever As Investors Focus On Decelerating US Demand For CARVYKTI Therapy
The company reported total revenue of $359.5 million for the quarter ended September 30, up 32% from $272.4 million a year earlier and roughly in line with expectations.